NIM
LAB icon

Needham Investment Management’s Standard BioTools LAB Stock Holding History

Needham Investment Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.3K Hold
34,435
– – ﹤0.01% 176
2026
Q1 		$31.7K Sell
34,435
-175,000
-84% -$212K ﹤0.01% 176
2025
Q4 		$268K Sell
209,435
-225,000
-52% -$302K 0.02% 160
2025
Q3 		$565K Hold
434,435
– – 0.04% 145
2025
Q2 		$521K Sell
434,435
-100,000
-19% -$111K 0.04% 141
2025
Q1 		$577K Sell
534,435
-200,000
-27% -$281K 0.05% 138
2024
Q4 		$1.29M Sell
734,435
-50,000
-6% -$93.1K 0.1% 124
2024
Q3 		$1.51M Sell
784,435
-200,000
-20% -$392K 0.12% 116
2024
Q2 		$1.74M Sell
984,435
-140,000
-12% -$342K 0.14% 113
2024
Q1 		$3.05M Hold
1,124,435
– – 0.28% 85
2023
Q4 		$2.49M Sell
1,124,435
-100,000
-8% -$213K 0.31% 79
2023
Q3 		$3.55M Sell
1,224,435
-810,000
-40% -$2.12M 0.6% 50
2023
Q2 		$3.93M Sell
2,034,435
-835,565
-29% -$1.65M 0.65% 47
2023
Q1 		$5.6M Sell
2,870,000
-927,157
-24% -$1.83M 0.97% 34
2022
Q4 		$4.44M Sell
3,797,157
-65,000
-2% -$80K 0.8% 42
2022
Q3 		$4.25M Sell
3,862,157
-11,746
-0.3% -$17.8K 0.83% 40
2022
Q2 		$6.2M Buy
3,873,903
+95,565
+3% +$236K 1.16% 32
2022
Q1 		$13.6M Buy
3,778,338
+263,338
+7% +$910K 1.96% 16
2021
Q4 		$13.8M Buy
3,515,000
+225,000
+7% +$1.05M 1.73% 18
2021
Q3 		$21.7M Buy
3,290,000
+39,750
+1% +$262K 2.89% 8
2021
Q2 		$20M Buy
3,250,250
+847,750
+35% +$4.53M 2.93% 8
2021
Q1 		$10.9M Buy
2,402,500
+1,152,500
+92% +$6.33M 1.48% 23
2020
Q4 		$7.5M Buy
1,250,000
+470,000
+60% +$3.09M 1.26% 29
2020
Q3 		$5.79M Buy
780,000
+217,500
+39% +$1.5M 1.16% 32
2020
Q2 		$2.26M Buy
+562,500
New +$1.96M 0.48% 58

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Needham Investment Management's LAB Position: Q2 2026 in Review

Needham Investment Management held its Standard BioTools (LAB) position steady in Q2 2026 at 34,435 shares worth $28.3K. The position accounts for ﹤0.01% of the portfolio, ranked #176.

Needham Investment Management first reported a position in LAB in Q2 2020 and has held it in 25 quarters since. The position peaked at $21.7M in Q3 2021. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Needham Investment Management held 34,435 shares of Standard BioTools worth $28.3K as of Q2 2026.
  • Needham Investment Management left its Standard BioTools share count unchanged in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Needham Investment Management's portfolio in Q2 2026, its #176 holding.
  • Needham Investment Management first reported a position in Standard BioTools in Q2 2020 and has held it in 25 quarters since.
  • Needham Investment Management's Standard BioTools position peaked at $21.7M in Q3 2021.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Needham Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.